Skip to main content

Search

Reset all filters
758 Result(s)
Sort by

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
FDA-approves-nintedanib-in-SSc-ILD

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
More health in vulnerable communities

More health in vulnerable communities

In an era of globalization and social connectivity, one-dimensional solutions often do not work anymore. Complex challenges need complex solutions.
Spesolimab Phase II data

Spesolimab Phase II data

New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
empulse-trial-benefit-acute-heart-failure

empulse-trial-benefit-acute-heart-failure

Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
Catherine Alonzo

Catherine Alonzo

Catherine Alonzo, Patient Safety Physician, Metabolism, tells us about the importance of drug surveillance.
EHS management approach

EHS management approach

We protect our employees, facilities and the environment from harmful influences, conserve natural resources and promote environmental awareness
Maria Weber

Maria Weber

Lead Patient Safety Physician Maria Weber tells us about why she joined Boehringer Ingelheim, and the importance of patient centricity in everything she does.
Vaccine prevent calf diarrhea

Vaccine prevent calf diarrhea

Fencovis® is the first vaccine to prevent calf diarrhea caused by E. coli F5 and bovine rotavirus and reduce severity of calf diarrhea caused by bovine coronavirus